Global Duchenne Muscular Dystrophy Drugs Market Insights and Forecast to 2026

Global Duchenne Muscular Dystrophy Drugs Market Insights and Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Duchenne Muscular Dystrophy Drugs Product Introduction
1.2 Market Segments
1.3 Key Duchenne Muscular Dystrophy Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type
1.4.2 Development & Drug Target
1.4.3 Mechanism of Action (MoA)
1.4.4 Route of Administration (RoA)
1.4.5 Molecule Type
1.5 Market by Application
1.5.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application
1.5.2 Hospitals and Clinics
1.5.3 Medical Laboratories
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Duchenne Muscular Dystrophy Drugs Market Size, Estimates and Forecasts
2.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue 2015-2026
2.1.2 Global Duchenne Muscular Dystrophy Drugs Sales 2015-2026
2.2 Global Duchenne Muscular Dystrophy Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Duchenne Muscular Dystrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Duchenne Muscular Dystrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Duchenne Muscular Dystrophy Drugs Competitor Landscape by Players
3.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers
3.1.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2015-2020)
3.1.2 Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers
3.2.1 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2019
3.2.5 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Duchenne Muscular Dystrophy Drugs Price by Manufacturers
3.4 Duchenne Muscular Dystrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Duchenne Muscular Dystrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Duchenne Muscular Dystrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2015-2020)
4.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020)
4.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2015-2020)
4.1.3 Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Duchenne Muscular Dystrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2015-2020)
5.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020)
5.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Application (2015-2020)
5.1.3 Duchenne Muscular Dystrophy Drugs Price by Application (2015-2020)
5.2 Duchenne Muscular Dystrophy Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Duchenne Muscular Dystrophy Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Duchenne Muscular Dystrophy Drugs by Country
6.1.1 North America Duchenne Muscular Dystrophy Drugs Sales by Country
6.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
6.3 North America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Drugs by Country
7.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Country
7.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Duchenne Muscular Dystrophy Drugs by Region
8.1.1 Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region
8.1.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
8.3 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Drugs by Country
9.1.1 Latin America Duchenne Muscular Dystrophy Drugs Sales by Country
9.1.2 Latin America Duchenne Muscular Dystrophy Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
9.3 Central & South America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs by Country
10.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Country
10.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Akashi Therapeutics Inc
11.1.1 Akashi Therapeutics Inc Corporation Information
11.1.2 Akashi Therapeutics Inc Description and Business Overview
11.1.3 Akashi Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.1.5 Akashi Therapeutics Inc Related Developments
11.2 Antisense Therapeutics Ltd
11.2.1 Antisense Therapeutics Ltd Corporation Information
11.2.2 Antisense Therapeutics Ltd Description and Business Overview
11.2.3 Antisense Therapeutics Ltd Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Products Offered
11.2.5 Antisense Therapeutics Ltd Related Developments
11.3 Beech Tree Labs Inc
11.3.1 Beech Tree Labs Inc Corporation Information
11.3.2 Beech Tree Labs Inc Description and Business Overview
11.3.3 Beech Tree Labs Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.3.5 Beech Tree Labs Inc Related Developments
11.4 Biogen Inc
11.4.1 Biogen Inc Corporation Information
11.4.2 Biogen Inc Description and Business Overview
11.4.3 Biogen Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Biogen Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.4.5 Biogen Inc Related Developments
11.5 Bioleaders Corp
11.5.1 Bioleaders Corp Corporation Information
11.5.2 Bioleaders Corp Description and Business Overview
11.5.3 Bioleaders Corp Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Products Offered
11.5.5 Bioleaders Corp Related Developments
11.6 BioMarin Pharmaceutical Inc
11.6.1 BioMarin Pharmaceutical Inc Corporation Information
11.6.2 BioMarin Pharmaceutical Inc Description and Business Overview
11.6.3 BioMarin Pharmaceutical Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.6.5 BioMarin Pharmaceutical Inc Related Developments
11.7 Biophytis SAS
11.7.1 Biophytis SAS Corporation Information
11.7.2 Biophytis SAS Description and Business Overview
11.7.3 Biophytis SAS Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Biophytis SAS Duchenne Muscular Dystrophy Drugs Products Offered
11.7.5 Biophytis SAS Related Developments
11.8 Capricor Therapeutics Inc
11.8.1 Capricor Therapeutics Inc Corporation Information
11.8.2 Capricor Therapeutics Inc Description and Business Overview
11.8.3 Capricor Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.8.5 Capricor Therapeutics Inc Related Developments
11.9 Catabasis Pharmaceuticals Inc
11.9.1 Catabasis Pharmaceuticals Inc Corporation Information
11.9.2 Catabasis Pharmaceuticals Inc Description and Business Overview
11.9.3 Catabasis Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.9.5 Catabasis Pharmaceuticals Inc Related Developments
11.10 CRISPR Therapeutics
11.10.1 CRISPR Therapeutics Corporation Information
11.10.2 CRISPR Therapeutics Description and Business Overview
11.10.3 CRISPR Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.10.4 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Products Offered
11.10.5 CRISPR Therapeutics Related Developments
11.1 Akashi Therapeutics Inc
11.1.1 Akashi Therapeutics Inc Corporation Information
11.1.2 Akashi Therapeutics Inc Description and Business Overview
11.1.3 Akashi Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.1.5 Akashi Therapeutics Inc Related Developments
11.12 Daiichi Sankyo Co Ltd
11.12.1 Daiichi Sankyo Co Ltd Corporation Information
11.12.2 Daiichi Sankyo Co Ltd Description and Business Overview
11.12.3 Daiichi Sankyo Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Daiichi Sankyo Co Ltd Products Offered
11.12.5 Daiichi Sankyo Co Ltd Related Developments
11.13 Debiopharm International SA
11.13.1 Debiopharm International SA Corporation Information
11.13.2 Debiopharm International SA Description and Business Overview
11.13.3 Debiopharm International SA Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Debiopharm International SA Products Offered
11.13.5 Debiopharm International SA Related Developments
11.14 Editas Medicine Inc
11.14.1 Editas Medicine Inc Corporation Information
11.14.2 Editas Medicine Inc Description and Business Overview
11.14.3 Editas Medicine Inc Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Editas Medicine Inc Products Offered
11.14.5 Editas Medicine Inc Related Developments
11.15 Eloxx Pharmaceuticals Inc
11.15.1 Eloxx Pharmaceuticals Inc Corporation Information
11.15.2 Eloxx Pharmaceuticals Inc Description and Business Overview
11.15.3 Eloxx Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Eloxx Pharmaceuticals Inc Products Offered
11.15.5 Eloxx Pharmaceuticals Inc Related Developments
11.16 F. Hoffmann-La Roche Ltd
11.16.1 F. Hoffmann-La Roche Ltd Corporation Information
11.16.2 F. Hoffmann-La Roche Ltd Description and Business Overview
11.16.3 F. Hoffmann-La Roche Ltd Sales, Revenue and Gross Margin (2015-2020)
11.16.4 F. Hoffmann-La Roche Ltd Products Offered
11.16.5 F. Hoffmann-La Roche Ltd Related Developments
11.17 FibroGen Inc
11.17.1 FibroGen Inc Corporation Information
11.17.2 FibroGen Inc Description and Business Overview
11.17.3 FibroGen Inc Sales, Revenue and Gross Margin (2015-2020)
11.17.4 FibroGen Inc Products Offered
11.17.5 FibroGen Inc Related Developments
11.18 Fulcrum Therapeutics Inc
11.18.1 Fulcrum Therapeutics Inc Corporation Information
11.18.2 Fulcrum Therapeutics Inc Description and Business Overview
11.18.3 Fulcrum Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Fulcrum Therapeutics Inc Products Offered
11.18.5 Fulcrum Therapeutics Inc Related Developments
11.19 Galapagos NV
11.19.1 Galapagos NV Corporation Information
11.19.2 Galapagos NV Description and Business Overview
11.19.3 Galapagos NV Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Galapagos NV Products Offered
11.19.5 Galapagos NV Related Developments
11.20 Genethon SA
11.20.1 Genethon SA Corporation Information
11.20.2 Genethon SA Description and Business Overview
11.20.3 Genethon SA Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Genethon SA Products Offered
11.20.5 Genethon SA Related Developments
11.21 GTx Inc
11.21.1 GTx Inc Corporation Information
11.21.2 GTx Inc Description and Business Overview
11.21.3 GTx Inc Sales, Revenue and Gross Margin (2015-2020)
11.21.4 GTx Inc Products Offered
11.21.5 GTx Inc Related Developments
11.22 Santhera Pharmaceuticals Holding AG
11.22.1 Santhera Pharmaceuticals Holding AG Corporation Information
11.22.2 Santhera Pharmaceuticals Holding AG Description and Business Overview
11.22.3 Santhera Pharmaceuticals Holding AG Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Santhera Pharmaceuticals Holding AG Products Offered
11.22.5 Santhera Pharmaceuticals Holding AG Related Developments
11.23 Sarepta Therapeutics Inc
11.23.1 Sarepta Therapeutics Inc Corporation Information
11.23.2 Sarepta Therapeutics Inc Description and Business Overview
11.23.3 Sarepta Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Sarepta Therapeutics Inc Products Offered
11.23.5 Sarepta Therapeutics Inc Related Developments
11.24 SOM Biotech SL
11.24.1 SOM Biotech SL Corporation Information
11.24.2 SOM Biotech SL Description and Business Overview
11.24.3 SOM Biotech SL Sales, Revenue and Gross Margin (2015-2020)
11.24.4 SOM Biotech SL Products Offered
11.24.5 SOM Biotech SL Related Developments
11.25 Strykagen Corp
11.25.1 Strykagen Corp Corporation Information
11.25.2 Strykagen Corp Description and Business Overview
11.25.3 Strykagen Corp Sales, Revenue and Gross Margin (2015-2020)
11.25.4 Strykagen Corp Products Offered
11.25.5 Strykagen Corp Related Developments
11.26 Summit Therapeutics Plc
11.26.1 Summit Therapeutics Plc Corporation Information
11.26.2 Summit Therapeutics Plc Description and Business Overview
11.26.3 Summit Therapeutics Plc Sales, Revenue and Gross Margin (2015-2020)
11.26.4 Summit Therapeutics Plc Products Offered
11.26.5 Summit Therapeutics Plc Related Developments
11.27 Taiho Pharmaceutical Co Ltd
11.27.1 Taiho Pharmaceutical Co Ltd Corporation Information
11.27.2 Taiho Pharmaceutical Co Ltd Description and Business Overview
11.27.3 Taiho Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.27.4 Taiho Pharmaceutical Co Ltd Products Offered
11.27.5 Taiho Pharmaceutical Co Ltd Related Developments
11.28 Teijin Pharma Ltd
11.28.1 Teijin Pharma Ltd Corporation Information
11.28.2 Teijin Pharma Ltd Description and Business Overview
11.28.3 Teijin Pharma Ltd Sales, Revenue and Gross Margin (2015-2020)
11.28.4 Teijin Pharma Ltd Products Offered
11.28.5 Teijin Pharma Ltd Related Developments
11.29 WAVE Life Sciences Ltd
11.29.1 WAVE Life Sciences Ltd Corporation Information
11.29.2 WAVE Life Sciences Ltd Description and Business Overview
11.29.3 WAVE Life Sciences Ltd Sales, Revenue and Gross Margin (2015-2020)
11.29.4 WAVE Life Sciences Ltd Products Offered
11.29.5 WAVE Life Sciences Ltd Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Duchenne Muscular Dystrophy Drugs Market Estimates and Projections by Region
12.1.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.2.2 North America: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Duchenne Muscular Dystrophy Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Duchenne Muscular Dystrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Duchenne Muscular Dystrophy Drugs Market Segments
Table 2. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Development & Drug Target
Table 5. Major Manufacturers of Mechanism of Action (MoA)
Table 6. Major Manufacturers of Route of Administration (RoA)
Table 7. Major Manufacturers of Molecule Type
Table 8. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global Duchenne Muscular Dystrophy Drugs Sales by Regions 2015-2020 (K Units)
Table 11. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Duchenne Muscular Dystrophy Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global Duchenne Muscular Dystrophy Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Duchenne Muscular Dystrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Duchenne Muscular Dystrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2019)
Table 17. Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Duchenne Muscular Dystrophy Drugs Price (2015-2020) (USD/Unit)
Table 20. Duchenne Muscular Dystrophy Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Duchenne Muscular Dystrophy Drugs Product Type
Table 22. Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 25. Global Duchenne Muscular Dystrophy Drugs Sales Share by Type (2015-2020)
Table 26. Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Type (2015-2020)
Table 28. Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 30. Global Duchenne Muscular Dystrophy Drugs Sales Share by Application (2015-2020)
Table 31. North America Duchenne Muscular Dystrophy Drugs Sales by Country (2015-2020) (K Units)
Table 32. North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Duchenne Muscular Dystrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 36. North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 38. North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Duchenne Muscular Dystrophy Drugs Sales by Country (2015-2020) (K Units)
Table 40. Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Duchenne Muscular Dystrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 44. Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 46. Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region (2015-2020) (K Units)
Table 48. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 52. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 54. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Duchenne Muscular Dystrophy Drugs Sales by Country (2015-2020) (K Units)
Table 56. Latin America Duchenne Muscular Dystrophy Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Duchenne Muscular Dystrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 60. Latin America Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 62. Latin America Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Country (2015-2020) (K Units)
Table 64. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 68. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 70. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 71. Akashi Therapeutics Inc Corporation Information
Table 72. Akashi Therapeutics Inc Description and Major Businesses
Table 73. Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 74. Akashi Therapeutics Inc Product
Table 75. Akashi Therapeutics Inc Recent Development
Table 76. Antisense Therapeutics Ltd Corporation Information
Table 77. Antisense Therapeutics Ltd Description and Major Businesses
Table 78. Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Antisense Therapeutics Ltd Product
Table 80. Antisense Therapeutics Ltd Recent Development
Table 81. Beech Tree Labs Inc Corporation Information
Table 82. Beech Tree Labs Inc Description and Major Businesses
Table 83. Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Beech Tree Labs Inc Product
Table 85. Beech Tree Labs Inc Recent Development
Table 86. Biogen Inc Corporation Information
Table 87. Biogen Inc Description and Major Businesses
Table 88. Biogen Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. Biogen Inc Product
Table 90. Biogen Inc Recent Development
Table 91. Bioleaders Corp Corporation Information
Table 92. Bioleaders Corp Description and Major Businesses
Table 93. Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. Bioleaders Corp Product
Table 95. Bioleaders Corp Recent Development
Table 96. BioMarin Pharmaceutical Inc Corporation Information
Table 97. BioMarin Pharmaceutical Inc Description and Major Businesses
Table 98. BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. BioMarin Pharmaceutical Inc Product
Table 100. BioMarin Pharmaceutical Inc Recent Development
Table 101. Biophytis SAS Corporation Information
Table 102. Biophytis SAS Description and Major Businesses
Table 103. Biophytis SAS Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. Biophytis SAS Product
Table 105. Biophytis SAS Recent Development
Table 106. Capricor Therapeutics Inc Corporation Information
Table 107. Capricor Therapeutics Inc Description and Major Businesses
Table 108. Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. Capricor Therapeutics Inc Product
Table 110. Capricor Therapeutics Inc Recent Development
Table 111. Catabasis Pharmaceuticals Inc Corporation Information
Table 112. Catabasis Pharmaceuticals Inc Description and Major Businesses
Table 113. Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. Catabasis Pharmaceuticals Inc Product
Table 115. Catabasis Pharmaceuticals Inc Recent Development
Table 116. CRISPR Therapeutics Corporation Information
Table 117. CRISPR Therapeutics Description and Major Businesses
Table 118. CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 119. CRISPR Therapeutics Product
Table 120. CRISPR Therapeutics Recent Development
Table 121. Cumberland Pharmaceuticals Inc Corporation Information
Table 122. Cumberland Pharmaceuticals Inc Description and Major Businesses
Table 123. Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 124. Cumberland Pharmaceuticals Inc Product
Table 125. Cumberland Pharmaceuticals Inc Recent Development
Table 126. Daiichi Sankyo Co Ltd Corporation Information
Table 127. Daiichi Sankyo Co Ltd Description and Major Businesses
Table 128. Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 129. Daiichi Sankyo Co Ltd Product
Table 130. Daiichi Sankyo Co Ltd Recent Development
Table 131. Debiopharm International SA Corporation Information
Table 132. Debiopharm International SA Description and Major Businesses
Table 133. Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 134. Debiopharm International SA Product
Table 135. Debiopharm International SA Recent Development
Table 136. Editas Medicine Inc Corporation Information
Table 137. Editas Medicine Inc Description and Major Businesses
Table 138. Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 139. Editas Medicine Inc Product
Table 140. Editas Medicine Inc Recent Development
Table 141. Eloxx Pharmaceuticals Inc Corporation Information
Table 142. Eloxx Pharmaceuticals Inc Description and Major Businesses
Table 143. Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 144. Eloxx Pharmaceuticals Inc Product
Table 145. Eloxx Pharmaceuticals Inc Recent Development
Table 146. F. Hoffmann-La Roche Ltd Corporation Information
Table 147. F. Hoffmann-La Roche Ltd Description and Major Businesses
Table 148. F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 149. F. Hoffmann-La Roche Ltd Product
Table 150. F. Hoffmann-La Roche Ltd Recent Development
Table 151. FibroGen Inc Corporation Information
Table 152. FibroGen Inc Description and Major Businesses
Table 153. FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 154. FibroGen Inc Product
Table 155. FibroGen Inc Recent Development
Table 156. Fulcrum Therapeutics Inc Corporation Information
Table 157. Fulcrum Therapeutics Inc Description and Major Businesses
Table 158. Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 159. Fulcrum Therapeutics Inc Product
Table 160. Fulcrum Therapeutics Inc Recent Development
Table 161. Galapagos NV Corporation Information
Table 162. Galapagos NV Description and Major Businesses
Table 163. Galapagos NV Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 164. Galapagos NV Product
Table 165.

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Testosterone Replacement Therapy Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 113

According to our LPI (LP Information) latest study, the global Testosterone Replacement Therapy market size was valued at US$ 1493.3 million in 2023. With growing demand in downstream market, the Testosterone Replacement Therapy is forecast to a readjusted size of US$ 1101.6 million by 2030 with a CAGR of -4.3% during review period. The research report highlights the growth potential of the global Testosterone Replacement Therapy market. Testosterone Replacement Therapy are expected to s......

Global Finasteride Tablets Market Research Report 2024

Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 96

The Finasteride Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Finasteride Tablets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profil......

Global Erectile Dysfunction Drugs Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 108

According to our LPI (LP Information) latest study, the global Erectile Dysfunction Drugs market size was valued at US$ 4749.4 million in 2023. With growing demand in downstream market, the Erectile Dysfunction Drugs is forecast to a readjusted size of US$ 7247.8 million by 2030 with a CAGR of 6.2% during review period. The research report highlights the growth potential of the global Erectile Dysfunction Drugs market. Erectile Dysfunction Drugs are expected to show stable growth in the ......

Global Methyltestosterone Market Research Report 2024

Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 75

The Methyltestosterone market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Methyltestosterone market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles......

Global Tamsulosin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 100

Market Overview of Global Tamsulosin market: According to our latest research, the global Tamsulosin market looks promising in the next 5 years. As of 2022, the global Tamsulosin market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Tamsulosin market, with a systematical de......

Global Erectile Dysfunction Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 112

Market Overview of Global Erectile Dysfunction Drug market: According to our latest research, the global Erectile Dysfunction Drug market looks promising in the next 5 years. As of 2022, the global Erectile Dysfunction Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the glo......

Global Finasteride Tablets Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 98

Market Overview of Global Finasteride Tablets market: According to our latest research, the global Finasteride Tablets market looks promising in the next 5 years. As of 2022, the global Finasteride Tablets market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Finasteride Ta......

Finasteride Tablets - Global Market Insights and Sales Trends 2024

Published: 19-Dec-2023        Price: US 3350 Onwards        Pages: 106

This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Finasteride Tablets, with both quantit......

Global Duchenne Muscular Dystrophy Drugs Market Research Report 2024 (Status and Outlook)

Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 134

Report Overview: The Global Duchenne Muscular Dystrophy Drugs Market Size was estimated at USD 8086.70 million in 2022 and is projected to reach USD 62734.28 million by 2029, exhibiting a CAGR of 34.00% during the forecast period. This report provides a deep insight into the global Duchenne Muscular Dystrophy Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development ......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs